| Cat. No. |
Product Name |
Information |
| PC-62561 |
CCT 068127
CDK2/9 inhibitor
|
CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively. |
| PC-62534 |
IIIM-290
CDK2/9 inhibitor
|
IIIM-290 (IIIM290) is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively. |
| PC-62302 |
THZ 531
CDK12/13 inhibitor
|
THZ 531 (THZ531) is a first-in-class, selective CDK12 and CDK13 covalent inhibitor with IC50 of 158 nM and 69 nM, respectively. |
| PC-61917 |
BS-194
CDK2 inhibitor
|
BS-194 (BS194) is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM). |
| PC-61916 |
ICEC 0942
CDK7 inhibitor
|
ICEC 0942 (Samuraciclib, CT7001) is a potent, selective, orally active CDK7 inhibitor with IC50 of 41 nM, displays 15-fold selectivity over CDK2 (IC50=578 nM). |
| PC-61405 |
AZ5576
CDK9 inhibitor
|
AZ5576 (AZ-5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM. |
| PC-61279 |
Riviciclib
CDK inhibitor
|
Riviciclib (P276-00 hydrochloride) is a potent CDK inhibitor with IC50 of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively. |
| PC-61248 |
CYC065
CDK2/9 inhibitor
|
CYC065 (Fadraciclib) is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9. |
| PC-61246 |
Roniciclib
CDK inhibitor
|
Roniciclib (BAY 1000394) is a potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM. |
| PC-61180 |
CDK7 and 9 inhibitor 14
CDK7/9 inhibitor
|
CDK7/9-IN-14 is a potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively. |
| PC-61146 |
CCT-251921
CDK8/CDK19 inhibitor
|
CCT-251921 (CCT251921) is a potent, selective, and orally bioavailable inhibitor of CDK8 and CDK19 with IC50of 2.3 nM and 2.6 nM respectively. |
| PC-61031 |
Voruciclib
CDK9 inhibitor
|
Voruciclib (P1446A-05) is a potent, selective and orally bioavailable CDK9 inhibitor with Ki of 0.63 nM and 1.68 nM for CDK9/cyclinT2 and CDK9/cyclinT1, respectively. |
